Abstract
The newly emerged coronavirus disease 2019 (COVID-19) seems to involve different organs, including the cardiovascular system. We systematically reviewed COVID-19 cardiac complications and calculated their pooled incidences. Secondarily, we compared the cardiac troponin I (cTnI) level between the surviving and expired patients. A systematic search was conducted for manuscripts published from December 1, 2019 to April 16, 2020. Cardiovascular complications, along with the levels of cTnI, creatine kinase (CK), and creatine kinase MB (CK-MB) in hospitalized PCR-confirmed COVID-19 patients were extracted. The pooled incidences of the extracted data were calculated, and the unadjusted cTnI level was compared between the surviving and expired patients. Out of 1094 obtained records, 22 studies on a total of 4,157 patients were included. The pooled incidence rate of arrhythmia was 10.11%. Furthermore, myocardial injury had a pooled incidence of 17.85%, and finally, the pooled incidence for heart failure was 22.34%. The pooled incidence rates of cTnI, CK-MB, and CK elevations were also reported at 15.16%, 10.92%, and 12.99%, respectively. Moreover, the pooled level of unadjusted cTnI was significantly higher in expired cases compared with the surviving (mean difference = 31.818, 95% CI = 17.923-45.713, P value <0.001). COVID-19 can affect different parts of the heart; however, the myocardium is more involved.
Highlights
On December 31, 2019, an atypical form of pneumonia was found in Wuhan city of China.[1]
The pathogen emerged in 2019, it quickly spread all around the world and caused a pandemic in 2020.4 It is estimated that around 25% to 35% of COVID-19 patients are at risk for deterioration who develop complications such as acute respiratory distress syndrome, arrhythmia, and shock
Selection Process Results Our search using the predefined search strategy yielded in 464, 409 and 221 studies from the Scopus, PubMed and Web of Science databases, respectively; 14 additional publications were added through searching the Google Scholar and three studies were added from reviewing the references list of the relevant studies
Summary
On December 31, 2019, an atypical form of pneumonia was found in Wuhan city of China.[1] On January 8, 2020, the Chinese Center for Disease Control and Prevention declared that the culprit pathogen for this atypical type of pneumonia was a new type of coronavirus.[2] This coronavirus was subsequently named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) causing “coronavirus disease 2019” (COVID-19).[3] the pathogen emerged in 2019, it quickly spread all around the world and caused a pandemic in 2020.4 It is estimated that around 25% to 35% of COVID-19 patients are at risk for deterioration who develop complications such as acute respiratory distress syndrome, arrhythmia, and shock. Arch Iran Med. 2021;24(2):152–163. doi: 10.34172/ aim.2021.24
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
